Trastuzumab: dreams, desperation and hope
Nature Reviews Cancer – In this World View, H. Michael Shepard describes his personal story behind the discovery of trastuzumab, 25 years since its FDA approval for HER2-overexpressing breast cancers.
Nature Reviews Cancer – In this World View, H. Michael Shepard describes his personal story behind the discovery of trastuzumab, 25 years since its FDA approval for HER2-overexpressing breast cancers.
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
Nature Communications – Papillary thyroid carcinoma has a heterogenous outcome, particularly in paediatric patients. Here, the authors utilise machine learning to create a protein-based prognostic…
Nature Reviews Cardiology – In this Review, the authors discuss the receptors, ligands and interactors that regulate immune cell recruitment in atherosclerosis, describe mechanisms that…
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
Learn more about what Crucial Catch is and how the NFL and ACS have teamed up to fight cancer. Find links to buy Crucial Catch…
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.
Nature Reviews Cancer – Using the tumour microenvironment to improve therapy efficacy